Us Fda Clears Armata Pharmas Ind Application To Start Phase 2 Trial Of Ap-Pa02 In Non-Cystic Fibrosis Bronchiectasis

Armata Pharmaceuticals, Inc. A Biotechnology Company, Announced That The Us Food And Drug Administration (Fda) Has Cleared Armata'S Investigational New Drug (Ind) Application To Initiate A Clinical Trial Of Its Optimized Lead Therapeutic Candidate, Ap-Pa02, In A Second Indication, Non-Cystic Fibrosis Bronchiectasis (Ncfb). The Company Plans To Initiate A Phase 2 Trial In 2022. In Patients With Ncfb, Lung Infection With Pseudomonas Aeruginosa Is Often Associated With Frequent Pulmonary Exacerbations, Reduced Quality Of Life, And Increased Mortality, And May Require Hospital Admission For Treatment. Although Chronic Inhaled Antibiotics Are Recommended For Long-Term Management Of Ncfb With Frequent Exacerbations, There Is Currently No Approved Therapy."We Are Excited To Gain Fda Clearance To Advance Ap-Pa02 Into Second Respiratory Indication," Said Brian Varnum, Chief Executive Officer Of Armata. "With This Regulatory Approval And Our Recent Financing, We Are Well Positioned To Explore The Clinical Benefit Of Ap-Pa02, And To Advance Ap-Sa02 For Prosthetic Joint Infections And Ap-Pa03 For Pneumonia."In Addition To The Upcoming Trial Of Ap-Pa02 In Ncfb, Armata Is Also Conducting A Phase 1B/2A Trial ('Swarm-P.A.') Of Ap-Pa02 Targeting Pseudomonas Aeruginosa Infections In Cystic Fibrosis Patients, And A Phase 1B/2A Trial ('Disarm') Of Ap-Sa02 Targeting Staphylococcus Aureus Bacteremia.Armata Is A Clinical-Stage Biotechnology Company Focused On The Development Of Precisely Targeted Bacteriophage Therapeutics For The Treatment Of Antibiotic-Resistant And Difficult-To-Treat Bacterial Infections Using Its Proprietary Bacteriophage-Based Technology.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!